Table 7.
North | % | South | % | East | % | |
Otoscopy | 169 | 78.2 | 211 | 93.8 | 135 | 73.4 |
Tympanometry | 142 | 65.7 | 172 | 76.4 | 56 | 30.4 |
Nasal endoscopy | 37 | 17.1 | 87 | 38.7 | 147 | 79.9 |
Pure tone audiometry | 162 | 75 | 186 | 82.7 | 151 | 82.1 |
High-frequency audiometry | 64 | 29.6 | 48 | 21.3 | 27 | 14.7 |
Speech audiometry | 119 | 55.1 | 93 | 41.3 | 44 | 23.9 |
Tinnitus pitch and loudness | 95 | 44 | 86 | 38.2 | 46 | 25 |
LDL | 2 | 0.9 | 1 | 0.4 | 0 | 0 |
MML | 1 | 0.5 | 0 | 0 | 0 | 0 |
RI | 1 | 0.5 | 0 | 0 | 0 | 0 |
Broadband noise EP | 0 | 0 | 0 | 0 | 0 | 0 |
Pure tone EP | 0 | 0 | 0 | 0 | 0 | 0 |
(DP)OAE | 68 | 31.5 | 54 | 24 | 35 | 19 |
AC-ASSR | 9 | 4.2 | 18 | 8 | 4 | 2.2 |
Electroencephalogram | 14 | 6.5 | 3 | 1.3 | 16 | 8.7 |
CT | 17 | 7.9 | 34 | 15.1 | 44 | 23.9 |
MRI | 76 | 35.2 | 119 | 52.9 | 100 | 54.3 |
Angio-MRI | 28 | 13 | 37 | 16.4 | 19 | 10.3 |
AC_ASSR, Air Conduction - Auditory Steady State Response; DP(OAE), Distortion Product (Oto-Acoustic Emissions); EP, Evoked Potential; LDL, Loudness Discomfort Level; MML, Minimum Masking Level; RI, Residual Inhibition.